CDC: No transmission found with HIV treatment, undetectable viral load | Ebola vaccine candidates trigger immune response in Liberia trial | Study: Switch to single-pill HIV regimen maintains safety, effectiveness
October 13, 2017
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
CDC: No transmission found with HIV treatment, undetectable viral load
HIV-positive individuals who take antiretroviral therapy and have undetectable viral loads have not transmitted HIV to HIV-negative partners in clinical trials, according to a CDC "Dear Colleague" letter. The findings were based on a review of three studies involving thousands of couples.
MD Magazine online (10/10) 
LinkedIn Twitter Facebook Google+ Email
Patient safety. Enhanced.
Trace amounts of anti-A and anti-B isoagglutinins in plasma-derived immunoglobulins have been associated with increased patient risk for hemolysis, a serious and sometimes fatal complication. Eshmuno® P anti-A/anti-B resins are specifically designed to…
Science & Health
Ebola vaccine candidates trigger immune response in Liberia trial
Two Ebola vaccine candidates tested in Liberia yielded immune responses that lasted at least one year and did not pose major safety concerns in patients with no history of Ebola, researchers reported in the New England Journal of Medicine. The study compared an adenovirus-based vaccine developed by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases, and a recombinant vesicular stomatitis virus-based vaccine developed by Canadian researchers and licensed by Merck.
Center for Infectious Disease Research and Policy (10/11) 
LinkedIn Twitter Facebook Google+ Email
Study: Switch to single-pill HIV regimen maintains safety, effectiveness
HIV patients taking protease inhibitors can safely shift to a one-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide without loss of efficacy, according to a Phase III trial presented at the IDWeek 2017 conference. A single-pill regimen is easier to take, which is associated with better outcomes, said session co-moderator Natasha Chida.
MedPage Today (free registration) (10/9) 
LinkedIn Twitter Facebook Google+ Email
Choose increased platelet availability
When the FDA issues final guidance regarding bacterial risk control strategies for platelets, you will have to decide which approach to use. Our Platelet PGD test is the ONLY way to enable 7-day platelet dating, which ensures a consistent platelet supply, simplifies inventory management and provides inventory flexibility for HLA matched units. Learn More.
Emerging Trends
New stem-cell method may lead to better understanding of miscarriage
Scientists have created special stem cells from the cells of very young mouse embryos that may one day be used to help prevent miscarriages, according to findings published in Nature. A mixture of chemicals keeps these stem cells, called expanded-potential stem cells, or EPSCs, in a young state that allows researchers to "erase all memories in these cells and take them back to the equivalent of a blank piece of paper," says study lead author Pentao Liu.
New Scientist (free content) (10/11) 
LinkedIn Twitter Facebook Google+ Email
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
Industry News & Practice
Wound repair researcher awarded $1.7M, named outstanding investigator
MDI Biological Laboratory researcher Vicki Losick has been awarded a $1.7 million grant and has been designated an outstanding investigator by the National Institute of General Medical Sciences, part of the NIH. Losick is studying wound repair at the Bar Harbor, Maine, facility.
Portland Press Herald (Maine) (10/11) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
NIH, 11 drugmakers collaborate on cancer therapy research
NIH, 11 drugmakers collaborate on cancer therapy research
The National Institutes of Health will collaborate with 11 drug companies in a $215 million public-private partnership to advance studies on immunotherapy research. The five-year Partnership for Accelerating Cancer Therapies will be devoted to identifying, developing and validating chemical signatures in the body to help determine which patients would benefit from cancer treatments.
Reuters (10/12),  STAT (tiered subscription model) (10/12) 
LinkedIn Twitter Facebook Google+ Email
Association News
AABB HUB: Hot topics this week
Topics currently creating a buzz in the AABB HUB include routine neonate cord blood testing and blood storage. The AABB HUB, the association's online community, provides access to discussions on hot topics in transfusion medicine, regulatory issues, cellular therapies, patient blood management and more. Join the HUB to follow these discussions or submit a comment and post or answer questions in one of the HUB's discussion groups.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
The people who get on in this world are the people who get up and look for the circumstances they want, and, if they can't find them, make them.
George Bernard Shaw,
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information